Earnings Call Summary | KNIGHT THERAPEUTICS INC(KHTRF.US) Q4 2023 Earnings Conference
Earnings Call Summary | KNIGHT THERAPEUTICS INC(KHTRF.US) Q4 2023 Earnings Conference
The following is a summary of the Knight Therapeutics Inc. (KHTRF) Q4 2023 Earnings Call Transcript:
以下是奈特療法公司（KHTRF）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Knight Therapeutics reported record revenues of $343 million in 2023, up by 18% compared to the prior year.
Q4 2023 revenues were over $88 million, a 5% increase year-over-year.
The company's adjusted EBITDA for 2023 was over $60 million, a growth of 11% from last year, representing about 18% of revenues.
Adjusted EBITDA per share was $0.59, a 23% increase year-over-year.
In the disease portfolio, oncology and hematology fetched $122.7 million, marking a 16% increase from last year, while infectious disease portfolio saw a 21% increase, delivering $141 million.
Knight also bought back 11.1 million common shares for over $53 million.
Knight Therapeutics報告稱，2023年收入達到創紀錄的3.43億美元，與去年同期相比增長了18％。
2023年第四季度收入超過8,800萬美元，同比增長5％。
該公司2023年調整後的息稅折舊攤銷前利潤超過6000萬美元，比去年增長11％，約佔收入的18％。
調整後的每股息稅折舊攤銷前利潤爲0.59美元，同比增長23％。
在疾病投資組合中，腫瘤學和血液學投資組合獲得了1.227億美元，比去年增長了16％，而傳染病投資組合增長了21％，達到1.41億美元。
奈特還以超過5,300萬美元的價格回購了1110萬股普通股。
Business Progress:
業務進展：
Knight Therapeutics made significant headway in its product pipeline in 2023, with regulatory filings for five products and approvals in certain territories. Two products were launched in Canada, two in Brazil, and one in Argentina.
In 2023, the company invested $2.5 million in nine pipeline products, which was an increase from the previous year.
New in-licensed products for 2024 include Qelbree (Canada) and IPX203 (Canada and Latin America) for ADHD and Parkinson's disease treatment respectively, and a branded generic molecule in oncology hematology for Brazil.
For 2024, the company projects revenues between $335 million to $350 million and adjusted EBITDA of approximately 17% of total revenues.
Knight Therapeutics在2023年在其產品管道中取得了重大進展，共有五種產品提交了監管申請，並在某些地區獲得了批准。兩款產品在加拿大推出，兩款在巴西推出，一款在阿根廷推出。
2023年，該公司在九種管道產品上投資了250萬美元，比上年有所增加。
2024 年新的許可產品包括分別用於治療注意力缺陷多動障礙和帕金森氏病的 Qelbree（加拿大）和 IPX203（加拿大和拉丁美洲），以及巴西腫瘤血液學中的品牌仿製分子。
該公司預計2024年的收入在3.35億美元至3.5億美元之間，調整後的息稅折舊攤銷前利潤約佔總收入的17％。
More details: KNIGHT THERAPEUTICS INC IR
更多詳情： 騎士療法公司IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。